Evidence map›Paper›PMID 32635833›Full record

ArticleTissue engineering. Part C, Methods2020

Soy Protein Nanofiber Scaffolds for Uniform Maturation of Human Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium.

Michael A Phelan, Kamil Kruczek, John H Wilson, Matthew J Brooks, Charles T Drinnan, Florian Regent, Jonathan A Gerstenhaber, Anand Swaroop, Peter I Lelkes, Tiansen Li

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tissue engineering. Part C, Methods, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Michael A PhelanNeurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Kamil KruczekNeurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
John H WilsonNeurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Matthew J BrooksNeurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Charles T DrinnanNeurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Florian RegentNeurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Jonathan A GerstenhaberIntegrated Laboratory for Cellular Tissue Engineering and Regenerative Medicine, Department of Bioengineering, College of Engineering, Temple University, Philadelphia, Pennsylvania, USA.
Anand SwaroopNeurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Peter I LelkesIntegrated Laboratory for Cellular Tissue Engineering and Regenerative Medicine, Department of Bioengineering, College of Engineering, Temple University, Philadelphia, Pennsylvania, USA.
Tiansen LiNeurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
National Institutes of Health · USNational Eye Institute · USTemple University · US

Funding

Mechanisms, modeling and therapies of retinal and macular neurodegenerationZIAEY000546 · NEI · NATIONAL EYE INSTITUTE · PI SWAROOP, ANAND · 2015 to 2025
$36.3M
Disease mechanism and therapies for retinal degenerationZIAEY000490 · NEI · NATIONAL EYE INSTITUTE · PI LI, TIANSEN · 2010 to 2025
$30.4M
6 · The paper itself

Abstract

Retinal pigment epithelium (RPE) differentiated from human induced pluripotent stem cells, called induced retinal pigment epithelium (iRPE), is being explored as a cell-based therapy for the treatment of retinal degenerative diseases, especially age-related macular degeneration. The success of RPE implantation is linked to the use of biomimetic scaffolds that simulate Bruch's membrane and promote RPE maturation and integration as a functional tissue. Due to difficulties associated with animal protein-derived scaffolds, including sterility and pro-inflammatory responses, current practices favor the use of synthetic polymers, such as polycaprolactone (PCL), for generating nanofibrous scaffolds. In this study, we tested the hypothesis that plant protein-derived fibrous scaffolds can provide favorable conditions permissive for the maturation of RPE tissue sheets

Indexed as

Cell DifferentiationCell LineElastic ModulusGene Expression ProfilingHumansHydrophobic and Hydrophilic InteractionsInduced Pluripotent Stem CellsNanofibersPolyestersRetinal Pigment EpitheliumSoybean ProteinsTissue ScaffoldspolycaprolactonePolyestersSoybean Proteinselectrospinninghuman iPSCsiRPEnanofibrous scaffoldRNA-seqsoy protein

Identifiers

PMID32635833
PMCPMC7462036
OpenAlexW3041878183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.